AZD-9291 is an irreversible inhibitor of EGFR. It is approved for the treatment of metastatic EGFR T790M mutation-positive non-small cell lung cancer (NSCLC) in patients failing previous tyrosine kinase therapy, and more recently also in T790M negative NSCLC patients. Combination therapy with pemetrexed and cisplatin is currently being studied to delay or overcome resistance to AZD-9291 that is commonly experienced by patients after prolonged treatment.
Uniformity of Dosage Units
Allschoolabs
Uniformity of Dosage Units is a specialised analytical laboratory service that assesses whether individual dosage units contain sufficiently consis...



































